Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era

Crit Rev Oncol Hematol. 2015 Feb;93(2):136-48. doi: 10.1016/j.critrevonc.2014.10.003. Epub 2014 Oct 17.

Abstract

Currently, androgen deprivation therapy (ADT) has a well-defined role when administered together with radiotherapy (RT): neo-adjuvant and concurrent combination for intermediate risk-disease and adjuvant therapy for high risk disease. Evidence of this association was generated by randomized trials designed and led approximately 30 years ago; thus the question which arises is how relevant and portable are these data in our current clinical practice? In the present review, we examine the pitfalls of these published randomized controlled trials, their relevance to present daily clinics, where high-dose external beam RT or brachytherapy is applied, as well as the adoption of ADT in patients with concomitant cardiovascular disorders.

Keywords: Androgen deprivation therapy; Brachytherapy.; Prostate cancer; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Brachytherapy / methods*
  • Combined Modality Therapy / methods*
  • Gene Expression
  • Humans
  • Male
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Radiotherapy Dosage
  • Randomized Controlled Trials as Topic
  • Receptors, Androgen / genetics*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Receptors, Androgen